NEW YORK
Pancreatic cancer has long held a grim distinction: it is one of the deadliest, most treatment-resistant cancers known. Fewer than 12% of patients survive five years after diagnosis. For decades, researchers have identified the genetic villain at the heart of most cases — a mutant protein called KRAS — but it remained stubbornly, maddeningly "undruggable." Until now.
On May 31, 2026, Revolution Medicines stepped onto the stage at the American Society of Clinical Oncology (ASCO) Annual Meeting and delivered results that left the oncology world speechless. Their experimental drug, daraxonrasib , had done what scientists once said could not be done: it locked onto the mutant KRAS protein, silenced it, and nearly doubled survival in metastatic pancreatic cancer.
The Numbers That Rewrote The Rulebook
The Phase 3 RASolute 302 trial involved 500 patients with previously treated metastatic pancreatic cancer.
Measure Chemotherapy Daraxonrasib
Median overall survival 6.7 months 13.2 months
Risk of death reduction — 60%
Progression-free survival 3.6 months 7.2 months
"We've never seen data like this presented in pancreatic cancer," said Dr. Shubham Pant, commenting at ASCO. "This is practice-changing."
The Genetic Lock That Scientists Finally Cracked
KRAS is a gene that produces a protein crucial to normal cell growth. In healthy cells, it acts like a light switch — turning on and off. In cancer, a mutation freezes the switch in the "on" position, driving uncontrolled growth.
KRAS mutations drive approximately 90% of pancreatic cancers , as well as substantial proportions of lung and colorectal cancers. Scientists identified KRAS as a key driver more than 40 years ago. Yet for four decades, every attempt to block it failed.
The problem was structural. KRAS's binding sites are extremely shallow — drugs had almost nothing to grip. Early candidates slid off like water off a windshield.
Daraxonrasib takes a different approach. Rather than trying to grip KRAS directly, it works through an intermediary protein called cyclophilin A. The drug binds to cyclophilin A, forming a molecular complex that then snaps onto the active KRAS protein and shuts it down. It is a molecular lock pick — and it works even against the "always-on" mutant form that previous drugs could not touch.
More than 91% of patients in the trial had a confirmed KRAS mutation — meaning daraxonrasib's benefits apply to the vast majority of pancreatic cancer patients.
FDA Fast-Tracks Access Even Before Approval
The magnitude of the results moved the FDA to act immediately. Within days of the ASCO presentation, the FDA allowed Revolution Medicines to launch an Expanded Access Program (EAP) , enabling seriously ill patients to receive the drug outside clinical trials.
By May 30, Revolution Medicines had begun shipping daraxonrasib to physicians and patients. For thousands of Americans living with previously treated metastatic pancreatic cancer, this represented a lifeline arriving faster than almost any comparable situation in FDA history.
The FDA also enrolled daraxonrasib in its Commissioner's National Priority Voucher pilot program, expediting review. Revolution Medicines will submit a New Drug Application (NDA), with potential full approval in early-to-mid 2027.
"For pancreatic cancer patients, this is the most significant advance we have seen in a generation," Dana-Farber Cancer Institute said in a news release.
Dana-Farber And The Science Behind The Molecule
Researchers at Dana-Farber noted that daraxonrasib's approach — targeting a co-factor protein rather than KRAS directly — represents a broader paradigm shift in how scientists are approaching "undruggable" targets.
"This is not just a win for pancreatic cancer patients," the release stated. "It is proof of concept that the undruggable can be drugged — and that approach will open doors for cancers driven by KRAS and other previously unreachable proteins across oncology."
Daraxonrasib is a RAS(ON) inhibitor — targeting the active state of KRAS regardless of which specific mutation drives it. This distinguishes it from earlier KRAS inhibitors (sotorasib, adagrasib), which only target narrow mutations and work only for a small subset of patients.
The Human Stakes: Who This Drug Could Help
Pancreatic cancer is diagnosed in approximately 66,000 Americans each year and kills approximately 51,000. Most patients are diagnosed at an advanced stage when surgery is impossible.
More than half are diagnosed with metastatic disease. For this group, median survival with current treatments has hovered around 10-12 months from diagnosis — and far less after first-line treatment fails. Daraxonrasib now offers something unprecedented for those whose cancer has progressed despite initial chemotherapy: a genuine second chance.
What Comes Next: The Road To Full Approval
Revolution Medicines is also evaluating daraxonrasib in other KRAS-driven cancers, including non-small cell lung cancer and colorectal cancer. Early phase trials are ongoing, and the scientific community is watching with extraordinary interest.
Insurance coverage under the expanded access program is handled case-by-case. Once formally approved, broader coverage will be required under most plans that cover cancer medications.
Expert Perspective: A Turning Point
Oncologists who have spent careers treating a disease defined by therapeutic futility described a sense of cautious, hard-won hope. Multiple experts noted that while 13 months is still not a cure — and pancreatic cancer remains devastating — it represents a fundamentally different trajectory.
"Doubling survival in any cancer is significant," one leading oncologist said. "Doubling survival in pancreatic cancer, with a well-tolerated oral pill targeting a mutation we've been chasing for 40 years — this is the kind of result that changes how we think about what's possible."
The Pancreatic Cancer Action Network described the results as "the most significant advance we have seen in a generation."
What This Means For You
If you or a loved one has metastatic pancreatic cancer that has progressed after at least one prior chemotherapy regimen, daraxonrasib may now be accessible through the Expanded Access Program. Speak with your oncologist about KRAS mutation testing — molecular tumor profiling is now standard of care for pancreatic cancer.
For the broader public, daraxonrasib's approval journey represents not just a drug, but proof of concept that could unlock treatments for lung cancer, colorectal cancer, and others driven by KRAS mutations.
And for the families of the 51,000 Americans who will die of pancreatic cancer this year — a number that, for the first time, researchers believe they may meaningfully change — it is the beginning of a different kind of story.
